| Title: |
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies |
| Authors: |
Taylor, Peter C; Kavanaugh, Arthur; Bessette, Louis; Fautrel, Bruno; Takeuchi, Tsutomu; Garrison, Andrew; Gao, Tianming; Lippe, Ralph; Caballero, Diane; Phillips, Charles; Mease, Philip J |
| Contributors: |
AbbVie Inc |
| Source: |
RMD Open ; volume 12, issue 1, page e005867 ; ISSN 2056-5933 |
| Publisher Information: |
BMJ |
| Publication Year: |
2026 |
| Description: |
Introduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain. Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflammation (AoI) versus remaining inflammation at weeks 12 and 24/26 (PsA/RA). Further, a mediation analysis assessed the direct/indirect effect of treatment on pain using the Patient’s Global Assessment of pain (PtGA) and 28 tender joint count (TJC28) at weeks 2/12/26 in RA, and weeks 16/24 in PsA. Results In patients with RA+AoI, PtGA scores improved more with upadacitinib (least squares mean change, –42.9) versus adalimumab (–34.7 (p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1136/rmdopen-2025-005867 |
| Availability: |
https://doi.org/10.1136/rmdopen-2025-005867; https://syndication.highwire.org/content/doi/10.1136/rmdopen-2025-005867 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.6CF7499 |
| Database: |
BASE |